Roundtable Discussion: Assessing the Pharmacological Impact of GPCR Biased Signaling, Endosomal Pathways & Oligomerization
- What are the current best practices for measuring GPCR signaling bias in vitro, and what limitations do they have for in vivo and clinical translation?
- What are the pros and cons of therapeutic targeting of oligomeric GPCRs? Are there targets that you think are especially promising for successful clinical translation?
- Are there current pharmacological tools for targeting endosomal GPCRs that may have broad translational potential? If not, why not?